These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 35405339)

  • 1. Inflammation targeted nanomedicines: Patents and applications in cancer therapy.
    Praveen TK; Gangadharappa HV; Abu Lila AS; Moin A; Mehmood K; Krishna KL; Hussain T; Alafnan A; Shakil S; Rizvi SMD
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):645-663. PubMed ID: 35405339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial intelligence aids in development of nanomedicines for cancer management.
    Tan P; Chen X; Zhang H; Wei Q; Luo K
    Semin Cancer Biol; 2023 Feb; 89():61-75. PubMed ID: 36682438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress and challenges in the translation of cancer nanomedicines.
    Tong F; Wang Y; Gao H
    Curr Opin Biotechnol; 2024 Feb; 85():103045. PubMed ID: 38096768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current nano-therapeutic approaches ameliorating inflammation in cancer progression.
    Rehman MU; Khan A; Imtiyaz Z; Ali S; Makeen HA; Rashid S; Arafah A
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):886-908. PubMed ID: 35143992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-Incorporated Nanomedicines for Cancer Therapy.
    Wu SY; Wu FG; Chen X
    Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.
    Balasubramanian V; Liu Z; Hirvonen J; Santos HA
    Adv Healthc Mater; 2018 Jan; 7(1):. PubMed ID: 28570787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
    Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
    Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress of Cancer Nanotechnology as Diagnostics, Therapeutics, and Theranostics Nanomedicine: Preclinical Promise and Translational Challenges.
    Alshehri S; Imam SS; Rizwanullah M; Akhter S; Mahdi W; Kazi M; Ahmad J
    Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33374391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedicines: intervention in inflammatory pathways of cancer.
    Anwar F; Naqvi S; Shams S; Sheikh RA; Al-Abbasi FA; Asseri AH; Baig MR; Kumar V
    Inflammopharmacology; 2023 Jun; 31(3):1199-1221. PubMed ID: 37060398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
    Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
    Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomedicines as cancer therapeutics: current status.
    Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
    Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation.
    Gu W; Meng F; Haag R; Zhong Z
    J Control Release; 2021 Jan; 329():676-695. PubMed ID: 33022328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology in inflammation: cutting-edge advances in diagnostics, therapeutics and theranostics.
    Liu Y; Lin Z; Wang Y; Chen L; Wang Y; Luo C
    Theranostics; 2024; 14(6):2490-2525. PubMed ID: 38646646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Nanomedicines for Cancer Treatment.
    do Nascimento T; Todeschini AR; Santos-Oliveira R; de Souza de Bustamante Monteiro MS; de Souza VT; Ricci-Júnior E
    Curr Pharm Des; 2020; 26(29):3579-3600. PubMed ID: 32186271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carrier-Free Nanomedicine for Cancer Immunotherapy.
    Fu Y; Bian X; Li P; Huang Y; Li C
    J Biomed Nanotechnol; 2022 Apr; 18(4):939-956. PubMed ID: 35854464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
    Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
    Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.